IDEAYA Biosciences IDYA announced positive clinical data from its mid-stage study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat heavily pre-treated methylthioadenosine phosphorylase (MTAP)-deletion urothelial (bladder) and non-small cell lung cancer (NSCLC) patients. Shares of the company soared 15.3% on Jun 8 in response. Management believes that theIDE397 study data demonstrates important clinical proof-of-concept in MTAP-deletion solid tumors to deliver meaningful responses and encourage preliminary durability of response with a convenient 30mg once-a-day tablet. IDE397 is IDEAYA’s potent and selective potential first-in-class MAT2A inhibitor. The phase II clinical data for IDE397, based on 18 evaluable patients with MTAP deletion, includes seven with urothelial cancer, four with adenocarcinoma NSCLC, and seven with squamous NSCLC. These patients were treated with the 30 mg expansion dose once a day. The reported clinical efficacy and tolerability data are preliminary, drawn from an investigator-reviewed unlocked database as of the cutoff date of Jun 21, 2024. Year to date, shares of IDEAYA have gained 11% against the industry’s 7.9% decline. Zacks Investment Research Image Source: Zacks Investment Research Per the data readout, the study achieved an overall response rate of 39%. Among the 18 evaluable patients, there was one complete response and six partial responses according to RECIST 1.1 evaluation. Two partial responses are pending confirmation, including a urothelial cancer patient with 100% tumor reduction and an adenocarcinoma NSCLC patient. The complete response and two partial responses were in urothelial cancer patients. Three partial responses were observed in squamous NSCLC patients and one in an adenocarcinoma NSCLC patient. One patient discontinued due to rapid disease progression and drug-unrelated adverse events. A disease control rate of 94% was also observed in the study. Furthermore, 14 out of 18 evaluable patients (78%) experienced tumor shrinkage. Additionally, 13 out of 16 patients, who represented 81% of the evaluable patient population, experienced a ctDNA reduction of 50% or more. The IDE397 expansion dose of 30 mg achieved target drug coverage and plasma S-adenosyl-l-methionine pharmacodynamic reduction associated with preclinical tumor regressions. IDEAYA reported that there were several quality control failures of patient samples that led to the unavailability of molecular response analysis. Also, at the time of the data readout, median duration of treatment, median duration of response, and median progression-free survival had not yet been reached. The company also reported that the 30 mg once-daily expansion dose of IDE397 was overall well tolerated with a favorable safety profile. No serious adverse events or discontinuations due to the drug were observed. Per IDEAYA, such a safety profile and convenient dosing schedule suggest the potential for long-term use and combination therapy development. The candidate is simultaneously being evaluated in combination with other approved drugs for NSCLC and urothelial cancer. Currently, no FDA-approved therapies exist for patients with MTAP-deletion solid tumors, representing a significant unmet medical need. IDE397's phase II monotherapy program prioritizes bladder cancer and NSCLC, where MTAP-deletion prevalence is more than 15% and 25%, respectively. Per IDEAYA, the estimated annual incidence of MTAP-deletion in NSCLC and urothelial cancer in the United States is about 48,000 patients. Additional tumor types, such as pancreatic, gastric, esophageal and head and neck cancers, are being considered for further development, with pancreatic cancer showing more than 20% MTAP-deletion prevalence, affecting approximately 14,000 patients annually in the United States. The company’s clinical-stage pipeline consists of two other investigational candidates, darovasertib (IDE196) and IDE161, which are being evaluated in separate studies for several cancer indications. IDEAYA Biosciences, Inc. Price and Consensus IDEAYA Biosciences, Inc. Price and Consensus IDEAYA Biosciences, Inc. price-consensus-chart | IDEAYA Biosciences, Inc. Quote Zacks Rank and Stocks to Consider IDEAYA currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks from the drug/biotech industryare ALX Oncology Holdings ALXO, Annovis Bio ANVS and Compugen CGEN. Each stock presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. In the past 30 days, the Zacks Consensus Estimate for ALX Oncology’s 2024 loss per share has remained constant at $2.89. During the same period, the consensus estimate for 2025 loss per share has remained constant at $2.73. Year to date, shares of ALXO have plunged 62.1%. ALX Oncology beat estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 8.83%. In the past 30 days, the Zacks Consensus Estimate for Annovis’ 2024 loss per share has remained constant at $2.46. During the same period, the consensus estimate for 2025 loss per share has remained constant at $1.95. Year to date, shares of ANVS have lost 17.3%. ANVS beat estimates in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%. In the past 30 days, the Zacks Consensus Estimate for Compugen’s 2024 earnings per share has remained constant at 5 cents. The consensus estimate for 2025 loss per share is currently pegged at 11 cents. Year to date, shares of CGEN have lost 13.6%. CGEN’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 5.79%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Compugen Ltd. (CGEN):Free Stock Analysis Report IDEAYA Biosciences, Inc. (IDYA):Free Stock Analysis Report Annovis Bio, Inc. (ANVS):Free Stock Analysis Report ALX Oncology Holdings Inc. (ALXO):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...